BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

27 related articles for article (PubMed ID: 38569907)

  • 1. FOXA1 and CK7 expression in esophageal squamous cell carcinoma and its prognostic significance.
    Xu Y; Wang W; Li L; Liu J; Wu X; Yu J; Wang H; Cui W; Zhang R
    Neoplasma; 2018 Mar; 65(3):469-476. PubMed ID: 29788741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytokeratin 7 is a predictive marker for survival in patients with esophageal squamous cell carcinoma.
    Oue N; Noguchi T; Anami K; Kitano S; Sakamoto N; Sentani K; Uraoka N; Aoyagi K; Yoshida T; Sasaki H; Yasui W
    Ann Surg Oncol; 2012 Jun; 19(6):1902-10. PubMed ID: 22203179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Expression of cytokeratin(CK)7, CK8/18, CK19 and p40 in esophageal squamous cell carcinoma and their correlation with prognosis].
    Yang ZY; Zhang HY; Wang F; Ma YH; Li YY; He HL; Wang C; Li SS
    Zhonghua Bing Li Xue Za Zhi; 2018 Nov; 47(11):834-839. PubMed ID: 30423606
    [No Abstract]   [Full Text] [Related]  

  • 4. Forkhead box A1 transcriptional pathway in KRT7-expressing esophageal squamous cell carcinomas with extensive lymph node metastasis.
    Sano M; Aoyagi K; Takahashi H; Kawamura T; Mabuchi T; Igaki H; Tachimori Y; Kato H; Ochiai A; Honda H; Nimura Y; Nagino M; Yoshida T; Sasaki H
    Int J Oncol; 2010 Feb; 36(2):321-30. PubMed ID: 20043065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of cytokeratin 7 predicts survival in stage I/IIA/IIB squamous cell carcinoma of the esophagus.
    Yamada A; Sasaki H; Aoyagi K; Sano M; Fujii S; Daiko H; Nishimura M; Yoshida T; Chiba T; Ochiai A
    Oncol Rep; 2008 Nov; 20(5):1021-7. PubMed ID: 18949396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FOXA1/CK7-positive Esophageal Squamous Cell Carcinoma with Aggressive Liver Metastasis: A Case Report.
    Inoue H; Inatomi O; Matsumoto H; Kimura H; Nakayama T; Nishida A; Andoh A
    Intern Med; 2024 Apr; ():. PubMed ID: 38569907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nivolumab combination therapy as first-line treatments for unresectable, advanced or metastatic esophageal squamous cell carcinoma.
    Rogers JE; Yamashita K; Sewastjanow-Silva M; Rosa Vicentini E; Waters R; Ajani JA
    Expert Rev Anticancer Ther; 2023 Jun; 23(6):565-571. PubMed ID: 37122102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Profile of Nivolumab in the Treatment of Resected Esophageal Squamous Cell Carcinoma: A Review of the Clinical Data.
    Kim Y; Yamamoto S; Kato K
    Cancer Manag Res; 2023; 15():399-406. PubMed ID: 37197006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pemphigus vulgaris as an immune-related adverse event in recurrent metastatic esophageal squamous cell carcinoma treated with ipilimumab plus nivolumab: a case report and literature review.
    Nakamura H; Shionoya A; Arihara Y; Hayasaka N; Kubo T; Usami M; Sugita S; Uhara H; Takada K
    Front Immunol; 2023; 14():1259071. PubMed ID: 37753079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Refractory solitary cervical lymph node metastasis after esophageal squamous cell carcinoma surgery and its successful treatment with immune checkpoint inhibitor: A case report and literature review.
    Song W; Wang H; Tian Y; Liu S; Chen X; Cui J; Zhao Y
    Medicine (Baltimore); 2020 Mar; 99(10):e19440. PubMed ID: 32150096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nivolumab in unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma.
    Ikeda G; Miyakoshi J; Yamamoto S; Kato K
    Future Oncol; 2024 Apr; 20(11):665-677. PubMed ID: 38126175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging data on nivolumab for esophageal squamous cell carcinoma.
    Hirose T; Yamamoto S; Kato K
    Expert Rev Gastroenterol Hepatol; 2021 Aug; 15(8):845-854. PubMed ID: 34251958
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.